Menu
← Oncology Approval Tracker
FDA DECISION ·
Opdivo + Yervoy
nivolumab + ipilimumab · Bristol Myers Squibb
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
For adults and children age 12 years or older with unresectable or metastatic MSI-high or mismatch repair-deficient colorectal cancer.
LAMPGEN ANALYSIS
Why it matters
FDA converted the earlier later-line accelerated use and broadened the label to include first-line treatment of unresectable or metastatic biomarker-selected disease.
What research teams should watch
Obtain mismatch repair or MSI results early and train teams to distinguish immune toxicity from symptoms of advanced colorectal cancer.
PRIMARY RECORDS